A randomized dental study found better pain control with a combined premedication strategy. Its design did not isolate alprazolam’s independent contribution.
Shetkar and colleagues studied 198 emergency patients with symptomatic irreversible pulpitis. Patients received one of three local-anesthetic block techniques, with subdivisions comparing placebo and premedication using alprazolam plus diclofenac potassium.
Pain scores improved across groups, and the premedication groups showed better pain control than their respective controls. Results also differed by local-anesthetic technique, emphasizing that the intervention was a combination of procedural and medication choices.
Because alprazolam was paired with an analgesic, the comparison cannot determine how much benefit came from anxiolysis, diclofenac, their interaction, or differences in the block. Calling this proof that alprazolam is an effective standalone dental analgesic would misstate the experiment.
Selection based on the studied dental condition and block-response criteria also limits application to other patients or procedures. Short-term pain scores do not establish long-term benefit or uncommon adverse-event rates.
Identify the entire regimen, including anti-inflammatory medication and local anesthesia. Sedation, anxiety relief, numbness, and pain reduction are distinct observations. The trial supports discussing the tested combined approach while leaving the independent effects of its components unresolved.
Original analysis of the supplied paper: Comparative evaluation of effect of preoperative alprazolam and diclofenac potassium on the success. Paper identifier: PMC5026094.